Olimab 60 Mg Injection

About Olimab 60 Mg Injection

Olimab 60 mg injection contains omalizumab as its active ingredient, which is a monoclonal antibody used to treat certain allergic conditions, particularly moderate to severe asthma and chronic urticaria (hives) that are not well controlled with other medications. Omalizumab works by binding to immunoglobulin E (IgE), an antibody involved in allergic reactions, thereby preventing it from interacting with its receptors on immune cells. This helps to reduce inflammation and allergic responses in the body.

For asthma, Olimab is typically prescribed to patients whose asthma is not controlled with inhaled corticosteroids or other asthma medications. It can help reduce the frequency of asthma attacks, improve lung function, and reduce the need for oral steroids. In chronic urticaria, it helps reduce the severity and frequency of hives and itching in patients who do not respond to antihistamine therapy.

The injection is usually administered once every 2 or 4 weeks, depending on the specific condition being treated and the patient's response to the medication. It is given as a subcutaneous (under the skin) injection by a healthcare provider, and the exact dose is determined based on factors such as the patients weight and the severity of the condition being treated.

Like any medication, Olimab 60 mg injection may cause side effects. Common side effects include reactions at the injection site (such as redness, swelling, or pain), headache, and upper respiratory infections. Less commonly, it may cause more serious side effects such as an allergic reaction, which can include symptoms like difficulty breathing, swelling of the face or throat, or rash. It is important to contact a healthcare provider immediately if any of these symptoms occur.

Patients should inform their doctor about any pre-existing conditions, such as a history of anaphylaxis, before starting treatment with Olimab. It is also important to continue using other prescribed asthma medications or allergy treatments unless otherwise directed by the healthcare provider.

Precision Therapy for Osteoporosis

Olimab 60 Mg Injection is a pharmaceutical-grade treatment developed for women with postmenopausal osteoporosis, especially those at heightened risk of fractures. Using advanced biotechnology, each pre-filled syringe delivers a precise 60 mg dose of denosumab, targeting bone loss via RANKL inhibition. Rigorous purity and ready-to-use packaging maximize patient safety and convenience.


Convenient and Controlled Administration

With its pre-filled syringe form, Olimab 60 Mg Injection ensures ease and accuracy. Administered subcutaneously by trained healthcare providers, this format minimizes preparation time and risk of dosing errors. The clear to slightly yellow sterile liquid is stable for up to 36 months when stored at the recommended refrigeration temperature, offering reliability in clinical settings.